| 40.53 -0.84 (-2.03%) | 03-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 49.48 | 1-year : | 52.99 |
| Resists | First : | 42.37 | Second : | 45.37 |
| Pivot price | 39.95 |
|||
| Supports | First : | 37.5 | Second : | 31.2 |
| MAs | MA(5) : | 39.91  |
MA(20) : | 40.42 |
| MA(100) : | 40.8 |
MA(250) : | 30.61 |
|
| MACD | MACD : | -0.9 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 30.6 |
D(3) : | 23.6 |
| RSI | RSI(14): 47.7 |
|||
| 52-week | High : | 56.04 | Low : | 18.53 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VERA ] has closed below upper band by 35.6%. Bollinger Bands are 58.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 42.26 - 42.47 | 42.47 - 42.67 |
| Low: | 39.56 - 39.81 | 39.81 - 40.06 |
| Close: | 40.06 - 40.46 | 40.46 - 40.86 |
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Fri, 20 Mar 2026
This $91 Million Investment Reflects Strong Confidence in a Biotech Firm Awaiting an FDA Ruling This Year - Bitget
Fri, 20 Mar 2026
Hudson Bay Capital Management LP Raises Holdings in Vera Therapeutics, Inc. $VERA - MarketBeat
Tue, 17 Mar 2026
Deep Track Capital, LP Increases Stake in Vera Therapeutics Inc - GuruFocus
Mon, 16 Mar 2026
Vera Therapeutics (VERA) finance chief exercises options for 10,000 shares - Stock Titan
Mon, 16 Mar 2026
Eversept Partners Increases Stake in Vera Therapeutics - Intellectia AI
Mon, 16 Mar 2026
HighVista Strategies LLC Increases Position in Vera Therapeutics, Inc. $VERA - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 113.9 (%) |
| Shares Short | 8,030 (K) |
| Shares Short P.Month | 8,050 (K) |
| EPS | -4.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.47 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.4 % |
| Return on Equity (ttm) | -50.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -241 (M) |
| Levered Free Cash Flow | -139 (M) |
| PE Ratio | -8.7 |
| PEG Ratio | 0 |
| Price to Book value | 4.77 |
| Price to Sales | 0 |
| Price to Cash Flow | -12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|